Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
Holding PBYI?
Track your performance easily
PBYI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $7.73
Previous Close$2.95
Volume400.58K
Average Volume (3M)323.13K
Market Cap
$144.69M
Enterprise Value$146.44M
Total Cash (Recent Filing)$96.83M
Total Debt (Recent Filing)$98.59M
Price to Earnings (P/E)16.1
Beta1.15
Next Earnings
Nov 07, 2024EPS Estimate
$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding49,046,723
10 Day Avg. Volume185,003
30 Day Avg. Volume323,135
Standard Deviation0.24
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.98
Price to Sales (P/S)0.66
Price to Cash Flow (P/CF)35.20
P/FCF Ratio35.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit0.85
Enterprise Value/Ebitda7.52
Forecast
1Y Price Target
$4.33Price Target Upside46.78% Upside
Rating ConsensusHold
Number of Analyst Covering3
Puma Biotechnology News
PremiumCompany Announcements
Puma Biotechnology Stockholders Elect Leadership and Approve Amendments
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPuma has initiated the ALISCA-Lung1 Phase 2 trial, advancing its research in treatment options for patients with extensive-stage SCLC.
EarningsPuma reported revenue and non-GAAP EPS that exceeded estimates, showcasing strong financial performance.
Product SalesU.S. Nerlynx sales have increased, reflecting growing market demand and successful sales strategies.
Bears Say
Financial PerformancePuma reported a GAAP net loss of $4.5 million, equating to a loss of $0.09 per share.
Operational GuidancePuma guided a net loss of between $6 million and $9 million in 2Q24.
Sales And RevenueNerlynx Q2 sales continue to be impacted by the low conversion from enrollment to patient starts.
---
Ownership Overview
31.83% Insiders
11.11% Mutual Funds
0.11% Other Institutional Investors
46.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.23 and its highest was $7.73 in the past 12 months.
What is Puma Biotechnology’s market cap?
Currently, no data Available
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Nov 07, 2024 which is in 2 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Aug 01, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.04.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is $0.33.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 49,046,722 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went up 9.429%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Among the largest hedge funds holding Puma Biotechnology’s share is Royce & Associates LLC. It holds Puma Biotechnology’s shares valued at 38K.
---
Puma Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.33 (46.78% Upside)
$4.33 (46.78% Upside)
Blogger Sentiment
Bullish
PBYI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 62.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $81.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.28%
12-Months-Change
Fundamentals
Return on Equity
22.10%
Trailing 12-Months
Asset Growth
2.25%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
---
PBYI Company Deck
---
PBYI Earnings Call
Q2 2024
0:00 / 0:00
---
PBYI Stock 12 Month Forecast
Average Price Target
$4.33
▲(46.78% Upside)
Technical Analysis
Best Analysts Covering PBYI
1 Year
1 Year Success Rate
16/26 ratings generated profit
1 Year Average Return
+4.23%
reiterated a buy rating 3 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +4.23% per trade.
---